Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(1)
•••
Comment by herbeapuceon Jul 24, 2018 8:33pm
161 Views
Post# 28362312

RE:RE:RE:Anyone emailed the communications team?

RE:RE:RE:Anyone emailed the communications team?
bigd1986 wrote: good to know. appreciate it



FYI I emailed their investor relation person on July 22nd in the evening regarding the Amsterdam AIDS convention.

I go an answer the next morning !  


I quote him : 

"Nous avons un reprsentant qui sera prsent. Il y a une prsentation sommaire sur des donnes pharmacoconomiques relies au traitement des patients VIH MDR."

Google translate: 

" We have a representative who will be present. There is a summary presentation on pharmacoeconomic data related to the treatment of MDR HIV patients."


So they do respond to emails, at least the easy ones..... 
Regards
Stef.


There is a summary presentation on pharmacoeconomic data related to the treatment of patientsThere is a summary presentation on pharmacoeconomic data related to the treatment of patientsThere is a summary presentation on pharmacoeconomic data related to the treatment of patientsThere is a summary presentation on pharmacoeconomic data related to the treatment of patients
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities